Skip to content
DataLookout
Menu

SCALANCT07725939

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 23 → 26 locations
  2. Minor Trial sites expanded: 13 → 23 locations
  3. Minor Trial sites expanded: 9 → 13 locations
  4. Minor Study sites: 7 to 9
  5. Notable Eligibility criteria expanded, about 13 words
    • Trial sites expanded: 4 → 7 locations
    • Secondary endpoints: details revised at 6 of 6 entries
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 3 to 4v5
  2. Minor Study sites: 1 to 3v4
  1. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 31, 2026 to Jul 27, 2026
    v3
  2. Notable Eligibility criteria expanded, about 1 wordv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Timeframe: Up to Week 60

Secondary (6)

Pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at 24 weeks
Annualized rate of moderate and severe AECOPD up to End of Treatment
Change from Baseline at Week 24 in St. George's Respiratory Questionnaire-COPD-specific version (SGRQ-C)
Proportion of participants with a decrease in SGRQ C total score of ≥4 points from Baseline to Week 24
Incidence of Treatment-Emergent (TE) Adverse Events (AE)
Show 1 moreShow less
Incidence of TE Serious Adverse Events (SAEs)

Arms and interventions

Galvokimig Dose 1 ArmExperimental

Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.

Galvokimig Dose 2 ArmExperimental

Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.

Placebo ArmPlacebo comparator

Participants randomly assigned to this arm will receive a matching Placebo.

Biologicals: Galvokimig, Placebo

Sites

26 sites in 2 countries

United States 16, China 10